viewZelira Therapeutics Ltd

Zelira Therapeutics cash balance boosted by $1.378 million R&D tax refund

The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

Zelira Therapeutics Ltd -
Zelira is a leading global therapeutic medical cannabis company with access to the world’s largest and fastest growing cannabis markets

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has received a A$1.378 million cash refund under the Australian Federal Government’s Research and Development (R&D) Tax Incentive Scheme.

The R&D Tax Incentive Scheme is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

Funds will be used to accelerate the recent launches of Zenivol™ for Insomnia, HOPE™ for Autism and a new CBD-Toothpaste into global markets and also to advance Zelira's ongoing clinical and product development programs.

Partnership with SprinJene®

In partnership with SprinJene®, a leader in natural oral care products, Zelira has launched its first over-the-counter (OTC) proprietary CBD toothpaste in the US.

The Zelira-SprinJene® CBD product will be distributed in the US through SprinJene’s existing distribution channels including retail stores such as Bed Bath & Beyond, Central Market, Sprouts, Lassen’s, Haggens, VitaCos and e-commerce platforms such as Amazon.

Discussions are ongoing to access SprinJene’s global distribution networks in France, Russia, the UK, Singapore, Ukraine, China, Morocco, United Arab Emirates, Saudi Arabia and Sudan Shoprite.

Zelira chief executive officer and managing director USA markets Dr Oludare Odumosu said: “Zelira is thrilled to enter the national oral care market alongside a company that values the harmony of nature and science as much as we do.”

Quick facts: Zelira Therapeutics Ltd

Price: 0.077 AUD

Market: ASX
Market Cap: $91.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...


Zelira Therapeutics sees 'multiple shots on goal' with a number of revenue...

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) deputy chairman Harry Karelis speaks to Proactive's Andrew Scott soon after announcing a strategic consolidation of its operations which sees leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the...

17 hours, 41 minutes ago

2 min read